We also cannot exclude the hypothesis that our samples of patients with SCD and aMCI were mostly composed of patients who will not evolve towards AD, due to the absence of amyloid-/tau-PET or CSF investigations in these participants and the negative structural/metabolic group-level neuroimaging findings (although again the small sample size may affect sensitivity). The gene discussed is MAPT; the disease is Alzheimer disease.